AFP and hepatocellular carcinoma: Additionally, they examined the use of APEX1 in stage 1 HCC with ROC analysis, revealing an AUC of 0.80 (p < 0.0001), which was considerably superior to AFP for the same stage (AUC of 0.607 with p = 0.0252) [14].